Chethan Ramamurthy, MD
Medical Oncology · San Antonio, TXNPI 1376805457
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Exelixis Inc. accounts for 68.2% of it on its own, with 3 other manufacturers making up the rest. 2022 is the largest year on record at $4,348, more than ten times the $20 reported in 2020. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 14 payments — averaging $455.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$4K
- Seagen Inc.$2K
- Johnson & Johnson$20
- Dendreon Pharmaceuticals LLC$18
Across 192 payments — averaging $9148.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$1.1M
- Gilead$438K
- Novartis$222K
- Mirati Therapeutics, Inc.$5K
- Immunomedics, Inc.$3K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$1,99231%
- Speaking & faculty fees$2,45038%
- Travel & lodging$1,50124%
- Food & beverage$4357%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 11 | $4,348 |
| Seagen Inc. | 1 | $1,992 |
| Johnson & Johnson | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,378 in reported general payments places this provider in the 50th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.